Searchable abstracts of presentations at key conferences in endocrinology

ea0011p644 | Neuroendocrinology and behaviour | ECE2006

Effects of targeted ablation of GHRH neurons in mice on anterior pituitary somatotrophs and lactotrophs

Miller A , Le Tissier P , Robinson I , Christian HC

Animal and clinical models of GHRH excess suggest that GHRH provides an important trophic drive to pituitary somatotrophs. Mice in which GHRH neurons have been ablated using a novel viral ion channel transgene (GHRH-M2 mice) show marked anterior pituitary hypoplasia and GH deficiency although GH cells are present. GHRH-M2 mice are also deficient in prolactin which is surprising as GHRH has little or no direct effect on PRL synthesis or release (Le Tissier, Mol Endo 19). In mic...

ea0010p21 | Clinical case reports/Governance | SFE2005

Non-alcoholic steatohepatitis (NASH) in a patient with Type 1 diabetes

Mehta S , Hameed A , Theofanoyiannis P , Robinson S , Valabhji J , Elkeles R

Non-alcoholic steatohepatitis is part of the spectrum of non-alcoholic fatty liver disease. It is characterised by triglyceride deposition in the liver associated with a lobular hepatitis and elevated circulating aminotransferases. It is associated with insulin resistance and commonly occurs in Type 2 diabetes but is much less widely recognised in patients with Type 1 diabetes.A 29 year old Caucasian male with longstanding Type 1 diabetes presented with ...

ea0029oc1.2 | Pituitary Clinical I | ICEECE2012

Patients with Cushing’s disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study

Bertagna X. , Pivonello R. , Fleseriu M. , Zhang Y. , Robinson P. , Taylor A. , Watson C. , Maldonado M. , Hamrahian A. , Boscaro M. , Biller B.

Introduction: The clinical features and complications of Cushing’s syndrome result from chronic excess of circulating cortisol, typically quantified by 24-h urinary free cortisol (UFC). LCI699 is a potent inhibitor of 11β-hydroxylase. Since 11β-hydroxylase catalyzes the final step of cortisol synthesis, LCI699 is a potential new treatment for all forms of Cushing’s syndrome.Methods: Adult patients with mild-to-severe Cushing’s di...

ea0010oc9 | Thyroid and pituitary | SFE2005

Association of the thyrotrophin receptor gene (TSHR) with Graves’ disease: evidence from independent UK population based case control and family studies

Brand O , Heward J , Brix T , Carr-Smith J , Connell J , Hegedus L , Hunt P , Robinson B , Wass J , Wiersinga W , Franklyn J , Weetman|S##Gough A

Genetic variants consistently associated with the development of Graves’ disease (GD) have, to date, been general autoimmunity loci including those within the HLA region, the CTLA-4 gene and most recently the PTPN22 gene encoding lymphoid tyrosine phosphatase (LYP). The thyrotophin receptor gene (TSHR) has recently however, been identified as the first Graves’ disease specific susceptibility locus. To further refine association with disease and exclude populat...